25I-NBOMe

25I-NBOMe (also known as 2C-I-NBOMe, Cimbi-5 and 25I) is a psychedelic hallucinogen that is used in biochemistry research for mapping the brain's usage of the type 2A serotonin receptor; it is also sometimes used for recreational purposes. A derivative of the phenethylamine 2C-I family, it is the most well-known member of the 25-NB family. It has been used in humans as a radioligand in SPECT imaging to map the distribution of 5-HT2A receptors in the brain.

History

25I-NBOMe was discovered in 2003 by Ralf Heim at the Free University of Berlin. It was further researched by a team at Purdue University led by David Nichols. The team was studying the benzyl substitution of 2C-I and its effects.

Pharmacology

25I-NBOMe is a full agonist of the human 5-HT2A receptor, which means it fully activates the receptor. The specific binding of 25I-NBOMe to the 5-HT2A receptor is thought to cause its psychedelic effects.

Effects

The effects of 25I-NBOMe can be very diverse and can range from euphoria to extreme hallucinations. The effects can last from six to ten hours, and can be followed by a period of insomnia.

Legal status

The legal status of 25I-NBOMe varies by country and is a controlled substance in many countries.

See also

• 2C-I
• Hallucinogen
• Psychedelic drug
• Ralf Heim
• David Nichols

References

25I-NBOMe Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski